Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population - PubMed (original) (raw)
. 2018 Apr;24(8 Suppl):S138-S145.
Affiliations
- PMID: 29693360
Free article
Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population
Eric T Wittbrodt et al. Am J Manag Care. 2018 Apr.
Free article
Abstract
Objectives: Guidance to industry from the FDA requires studies to evaluate the cardiovascular safety of novel type 2 diabetes (T2D) medications. Although the objectives of such cardiovascular outcomes trials (CVOTs) are similar, differences in features such as enrollment criteria present a challenge when trying to assess the applicability of these studies to real-world T2D populations. This study evaluated the proportions of US adults with T2D who met the eligibility criteria for each of the 4 sodium-glucose cotransporter-2 (SGLT2) inhibitor CVOTs.
Study design: A cross-sectional retrospective study was conducted using data from the National Health and Nutrition Examination Survey (NHANES) and published patient eligibility criteria for completed or ongoing SGLT2 inhibitor CVOTs.
Methods: Data on T2D diagnosis and other relevant clinical and demographic characteristics were extracted from the NHANES (2009-2010 and 2011-2012). Weighted analysis of these data was used to estimate the percentage of US adults with T2D who met the eligibility criteria for the CANVAS program (CANagliflozin cardioVascular Assessment Study) (canagliflozin; NCT01032629, NCT01989754), and the DECLARE-TIMI 58 (dapagliflozin; NCT01730534), EMPA-REG OUTCOME (empagliflozin; NCT01131676), and VERTIS-CV (ertugliflozin; NCT01986881) trials.
Results: The weighted analysis identified a population of 23,941,512 US adults from data on key inclusion criteria and information indicating a diagnosis of T2D. Of these, 4.1% met the criteria for EMPA-REG OUTCOME, 4.8% for VERTIS-CV, 8.8% for the CANVAS program, and 39.8% for the DECLARE-TIMI 58 trial.
Conclusions: There were considerable differences in the proportions of US adults with T2D who met the eligibility criteria for these studies.The DECLARE-TIMI 58 trial criteria were the most generalizable to the US T2D population.
Similar articles
- Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice.
Nicolucci A, Candido R, Cucinotta D, Graziano G, Rocca A, Rossi MC, Tuccinardi F, Manicardi V. Nicolucci A, et al. Adv Ther. 2019 Oct;36(10):2895-2909. doi: 10.1007/s12325-019-01043-z. Epub 2019 Aug 13. Adv Ther. 2019. PMID: 31410779 - Cardiorenal Outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME Trials: A Systematic Review.
Kluger AY, Tecson KM, Barbin CM, Lee AY, Lerma EV, Rosol ZP, Rangaswami J, Lepor NE, Cobble ME, McCullough PA. Kluger AY, et al. Rev Cardiovasc Med. 2018 Jun 30;19(2):41-49. doi: 10.31083/j.rcm.2018.02.907. Rev Cardiovasc Med. 2018. PMID: 31032602 - Class effects of SGLT2 inhibitors on cardiorenal outcomes.
Kluger AY, Tecson KM, Lee AY, Lerma EV, Rangaswami J, Lepor NE, Cobble ME, McCullough PA. Kluger AY, et al. Cardiovasc Diabetol. 2019 Aug 5;18(1):99. doi: 10.1186/s12933-019-0903-4. Cardiovasc Diabetol. 2019. PMID: 31382965 Free PMC article. Review. - Eligibility of patients with type 2 diabetes for sodium-glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study.
Pintat S, Fenici P, Hammar N, Ji L, Khunti K, Medina J, Tang F, Wittbrodt E, Surmont F. Pintat S, et al. BMJ Open Diabetes Res Care. 2019 Mar 21;7(1):e000627. doi: 10.1136/bmjdrc-2018-000627. eCollection 2019. BMJ Open Diabetes Res Care. 2019. PMID: 31114700 Free PMC article. - Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
Handelsman Y. Handelsman Y. Adv Ther. 2019 Oct;36(10):2567-2586. doi: 10.1007/s12325-019-01054-w. Epub 2019 Aug 23. Adv Ther. 2019. PMID: 31444707 Free PMC article. Review.
Cited by
- Cost Offset of Dapagliflozin in the US Medicare Population with Cardio-Kidney Metabolic Syndrome.
Chang RC, Miller RL, Kwon KW, Huang JC. Chang RC, et al. Adv Ther. 2024 Aug;41(8):3247-3263. doi: 10.1007/s12325-024-02919-5. Epub 2024 Jul 3. Adv Ther. 2024. PMID: 38958842 Free PMC article. - Gender disparities in time-to-initiation of cardioprotective glucose-lowering drugs in patients with type 2 diabetes and cardiovascular disease: a Danish nationwide cohort study.
Funck KL, Bjerg L, Isaksen AA, Sandbæk A, Grove EL. Funck KL, et al. Cardiovasc Diabetol. 2022 Dec 10;21(1):279. doi: 10.1186/s12933-022-01713-3. Cardiovasc Diabetol. 2022. PMID: 36496402 Free PMC article. - Is HbA1c a valid surrogate for mortality in type 2 diabetes? Evidence from a meta-analysis of randomized trials.
Baechle C, Scherler W, Lang A, Filla T, Kuss O. Baechle C, et al. Acta Diabetol. 2022 Oct;59(10):1257-1263. doi: 10.1007/s00592-022-01887-y. Epub 2022 May 9. Acta Diabetol. 2022. PMID: 35534726 Free PMC article. Review. - Phenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes.
Oikonomou EK, Suchard MA, McGuire DK, Khera R. Oikonomou EK, et al. Diabetes Care. 2022 Apr 1;45(4):965-974. doi: 10.2337/dc21-1765. Diabetes Care. 2022. PMID: 35120199 Free PMC article. Clinical Trial. - A Comparison of Individuals with Diabetes and EMPA-REG Trial Participants: Exploring Aspects of External Validity.
Chaitoff A, Niforatos JD, Gong J, Fischer MA. Chaitoff A, et al. J Gen Intern Med. 2022 Aug;37(11):2744-2750. doi: 10.1007/s11606-021-07284-5. Epub 2022 Jan 14. J Gen Intern Med. 2022. PMID: 35031947 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous